GGrantIndex
← Leaderboards

Dikoma C. Shungu

Columbia University Health Sciences

Google Scholar ↗PubMed ↗ORCID ↗
$12,054,848
Attributed
$14,535,426
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.4M · FY2007–25
$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$23,942,154 · 11

By mechanism

R01$10,913,182 · 4
U54$10,877,091 · 2
R21$933,378 · 2
R34$617,981 · 1
S10$482,000 · 1
R29$118,522 · 1

Top collaborators

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Magnetic Resonance Spectroscopy”

Research focus

Magnetic Resonance SpectroscopyBrainSymptomsIn VivoProtonsBaseReportingGlutathioneOxidative StressFunctional DisorderChronic Fatigue SyndromeResponseFatigueMusculoskeletal PainBiological MarkersRestSleep DisturbancesHeadacheNeuroimagingDiagnostic TestsCohortGrantMultidisciplinaryResearch Personnel

Grant awards (38)

Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement$524,792
R01 · FY2025 · NS · contact PI
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement$583,100
R01 · FY2023 · NS · contact PI
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement$583,100
R01 · FY2022 · NS · contact PI
Cornell ME/CFS Collaborative Research Center$1,922,881
U54 · FY2021 · NS
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$686,941
R01 · FY2021 · MH · contact PI
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement$583,100
R01 · FY2021 · NS · contact PI
Oxidative Stress and Neuroinflammation: Co-conspirators in ME/CFS Pathophysiology$178,793
U54 · FY2021 · NS · contact PI
Cornell ME/CFS Collaborative Research Center$1,916,014
U54 · FY2020 · NS
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$696,494
R01 · FY2020 · MH · contact PI
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement$586,263
R01 · FY2020 · NS · contact PI
Oxidative Stress and Neuroinflammation: Co-conspirators in ME/CFS Pathophysiology$178,291
U54 · FY2020 · NS · contact PI
Cornell ME/CFS Collaborative Research Center$1,849,848
U54 · FY2019 · NS
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$707,540
R01 · FY2019 · MH · contact PI
Oxidative Stress and Neuroinflammation: Co-conspirators in ME/CFS Pathophysiology$366,482
U54 · FY2019 · NS · contact PI
Cornell ME/CFS Collaborative Research Center$1,849,148
U54 · FY2018 · NS
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$780,214
R01 · FY2018 · MH · contact PI
Oxidative Stress and Neuroinflammation: Co-conspirators in ME/CFS Pathophysiology$366,417
U54 · FY2018 · NS · contact PI
Cornell ME/CFS Collaborative Research Center$1,868,837
U54 · FY2017 · NS
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia$849,678
R01 · FY2017 · MH · contact PI
Oxidative Stress and Neuroinflammation: Co-conspirators in ME/CFS Pathophysiology$380,380
U54 · FY2017 · NS · contact PI
Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome$494,315
R01 · FY2016 · MH · contact PI
Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome$499,000
R01 · FY2015 · MH · contact PI
Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome$499,000
R01 · FY2014 · MH · contact PI
2/2-Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD$203,748
R34 · FY2014 · MH · contact PI
Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome$499,000
R01 · FY2013 · MH · contact PI
NAC for Treatment of Oxidative Stress in Chronic Fatigue Syndrome$199,152
R21 · FY2013 · NR · contact PI
2/2-Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD$194,827
R34 · FY2013 · MH · contact PI
NAC for Treatment of Oxidative Stress in Chronic Fatigue Syndrome$269,536
R21 · FY2012 · NR · contact PI
N-Acetylcysteine for Neuroprotection in Parkinson's Disease$220,564
R21 · FY2012 · AG · contact PI
2/2-Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD$219,406
R34 · FY2012 · MH · contact PI
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia$495,542
R01 · FY2011 · MH · contact PI
N-Acetylcysteine for Neuroprotection in Parkinson's Disease$244,126
R21 · FY2011 · AG · contact PI
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia$512,079
R01 · FY2010 · MH · contact PI
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia$489,177
R01 · FY2009 · MH · contact PI
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia$424,460
R01 · FY2008 · MH · contact PI
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia$419,387
R01 · FY2007 · MH · contact PI
CONSOLE UPGRADE FOR A 4.23 T WHOLE-BODY MR SYSTEM$482,000
S10 · FY2000 · RR
QUANTATIVE HIGH FIELD CLINICAL 1H MR NEUROSPECTROSCOPY$118,522
R29 · FY2000 · NS